Clinical trials: AD - Alzheimer's Disease
Alzheimer Disease, Healthy
Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease
Inflammation occurs in many brain diseases including Alzheimer's disease. In Alzheimer's disease, an abnormal protein called amyloid starts accumulating decades before the start of forgetfulness.
- Trial name
- NCT05582200
- Testing
- Positron Emission Tomography (PET) using 11C-ER176 for TSPO and 18F-SMBT1 for MAO-B
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Alzheimer's Disease, Dementia
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
This study will evaluate acute symptomatic improvements in cognitive performance in healthy elderly participants with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00874939
- Testing
- MK-0249 7.5 mg, MK-0249 25 mg, Donepezil 5mg
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Monetary Cost of Alzheimer's Disease in China
The purpose of the study is to estimate the Chinese economic burden in patients with Alzheimer's Disease (AD).
- Trial name
- NCT02694445
- Testing
- observation
- Where
- China
- Volunteers
- 3,098 people
- Sponsor
- Beijing Friendship Hospital
Alzheimer Disease, MCI
Validation Study of a New Digital Treatment Test
Oculomotor behavior and cognitive processing of visual information are intimately connected. AD patients show ocular movement problems.
- Trial name
- NCT04897464
- Testing
- BGaze therapy Alzheimer
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Braingaze
Aging, Mild Cognitive Impairment
SMART: Somatotrophics, Memory, and Aging Research Trial
The purpose of the SMART study was to better understand whether the body's own production of growth hormone (GH) would improve memory and problem solving ability, or cognitive function.
- Trial name
- NCT00257712
- Testing
- TH9507 human growth hormone releasing hormone (GHRH)
- Where
- United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- University of Washington
Alzheimer's Disease
A Safety and Tolerability Study of ABT-126 in Elderly
The objectives of this study are to assess the safety, tolerability and pharmacokinetics of ABT-126 in elderly subjects.
- Trial name
- NCT00867399
- Testing
- ABT-126
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Abbott
Alzheimer Disease, Telerehabilitation
Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease
Our aim has been determined to investigate the effect of physical exercise alone and in combination with cognitive exercise, on cognitive, physical function and quality of life in individuals with Alzheimer's Disease during the…
- Conditions
- Alzheimer Disease, Telerehabilitation, Online Physical Exercise, Computerized Cognitive Stimulation
- Trial name
- NCT04842734
- Testing
- Physical exercise, Physical exercise and computerized cognitive training
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Yeditepe University
Alzheimer Disease, Mild Cognitive Impairment
Brain Energy for Amyloid Transformation in Alzheimer's Disease Study
The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults with mild cognitive impairment.
- Trial name
- BEAT-AD (NCT03472664)
- Testing
- low carbohydrate/high fat diet, low fat/high carbohydrate diet
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Wake Forest University Health Sciences
Alzheimer Disease
Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease
The aim of this study is to evaluate the safety, feasibility, tolerability and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer's disease.
- Trial name
- BUENA (NCT03402503)
- Testing
- Montelukast buccal film
- Where
- 12 sites in Canada
- Volunteers
- 52 people
- Sponsor
- IntelGenx Corp.
Alzheimer Disease
A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease
Lexical semantic disorders are described in Alzheimer's disease, and their incidence in everyday life is important to the extent that these disorders affect expression and comprehension.
- Trial name
- SemantiMATT (NCT03047694)
- Testing
- tablet therapy, usual care
- Where
- 2 sites in France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer's Disease
A Safety Study of LY2886721 Single Doses in Healthy Subjects
This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 single doses, how the body handles the drug, and the drug's effect on the body.
- Trial name
- NCT01133405
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Memory Impairment Study (Mild Cognitive Impairment Study)
The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia.
- Trial name
- NCT00000173
- Testing
- Donepezil, Vitamin E
- Where
- 72 sites in United States, Canada
- Sponsor
- National Institute on Aging (NIA)
Alzheimer Disease
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early…
- Trial name
- ALTITUDE-AD (NCT06335173)
- Testing
- sabirnetug
- Where
- 68 sites in United States, Canada and 3 more
- Volunteers
- 542 people
- Sponsor
- Acumen Pharmaceuticals
Healthy Elderly
MAD Study of NX210c
This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.
- Trial name
- CHDR2235 (NCT05827653)
- Testing
- NX210c
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Axoltis Pharma
Alzheimer's Disease
Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia
The purpose of this study is to determine the safety, tolerability and effect of JNJ-54861911 on level of amyloid-beta in Cerebrospinal Fluid (CSF) and plasma following 4 weeks of treatment in Japanese participants asymptomatic…
- Trial name
- NCT02360657
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 50 mg
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Janssen Pharmaceutical K.K.
Alzheimer's Disease
Control and Intervention Programme on Alzheimer's Disease Risk Factors
Recent epidemiologic studies are identifying a number of modifiable risk and protective factors that may influence in the incidence of Alzheimer's disease (AD).
- Trial name
- ALFAlife (NCT02772523)
- Testing
- Lifestyle recommendations
- Where
- Spain
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Healthy Aging, Alzheimer Disease
Acute Exercise and the Cerebral Metabolic Response in Aging and Alzheimer's Disease
The overall goal is to characterize the acute exercise response as it relates to brain glucose metabolism in aging and Alzheimer's Disease (AD).
- Trial name
- AEROBIC (NCT04299308)
- Testing
- Aerobic Exercise
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Alzheimer's Disease
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
To investigate the clinical safety and effectiveness of donepezil hydrochloride administration in patients with mild or moderate Alzheimer's Disease
- Trial name
- NCT01251718
- Testing
- donepezil hydrochloride
- Where
- 106 sites in Japan
- Volunteers
- 894 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer's Disease
Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients
Cholinergic neurons in the basal forebrain project widely to the cerebral cortex and hippocampus. These neurons depend on nerve growth factor (NGF) from their target areas for survival.
- Trial name
- NsG0202 (NCT01163825)
- Testing
- Nerve Growth Factor
- Where
- Sweden
- Volunteers
- 6 people
- Sponsor
- NsGene A/S
Alzheimer's Disease
Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
This is a multiple vaccination study to find out if it is a safe treatment and what effects it has on the symptoms of early Alzheimer's disease in male and female patients aged 50 to 80 years.
- Trial name
- NCT01117818
- Testing
- active: AFFITOPE AD02
- Where
- 31 sites in Austria, Croatia and 4 more
- Volunteers
- 335 people
- Sponsor
- Affiris AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.